Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

ClinicalTrials.gov ID: NCT05308264

Public ClinicalTrials.gov record NCT05308264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Study identification

NCT ID: NCT05308264
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Rigel Pharmaceuticals; Industry
Enrollment: 86 participants

Conditions and interventions

Conditions

Low Risk Myelodysplastic Syndromes

Interventions

R906289 Monosodium (R289 Na) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 11, 2022
Primary completion: Jul 31, 2026
Completion: Nov 30, 2026
Last update posted: Aug 9, 2026

2022 – 2026

United States locations

U.S. sites: 15
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of California, Los Angeles	Los Angeles	California	90095	Recruiting
University of California, Irvine	Orange	California	92868	Recruiting
Stanford Cancer Institute	Palo Alto	California	94304	Recruiting
University of Miami	Miami	Florida	33136	Recruiting
Mount Sinai Medical Center	Miami Beach	Florida	33140	Withdrawn
WashU Medicine	St Louis	Missouri	63110	Recruiting
Oncology Clinical Research Referral Office	Hackensack	New Jersey	07601	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	09083	Withdrawn
Ichan School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Duke Cancer Institute	Durham	North Carolina	27705	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
University of Texas, Southwestern	Dallas	Texas	75390	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Intermountain Healthcare	Salt Lake City	Utah	84009	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05308264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05308264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →